We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb Co. (BMY - Free Report) , Honeywell International Inc. (HON - Free Report) , Sony Group Corp. (SONY - Free Report) , Airbnb, Inc. (ABNB - Free Report) and Republic Services, Inc. (RSG - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Bristol-Myers, Honeywell and Sony
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb Co., Honeywell International Inc. and Sony Group Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Bristol-Myers Squibb’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+11.3% vs. -13.9%) on the back of solid demand outlook for the company’s blood thinner drug Eliquis and the label expansion of Opdivo. Eliquis is the leading oral anticoagulant drug and continues to experience growth in its market share.
The label expansion of Opdivo into indications for lung cancer, renal cancer and gastric cancer boosted sales. The recent approval of drugs like Opdualag, Breyanzi and Sotyktu will add a new stream of revenues.
According to the Zacks analyst's estimate, the BMY’s top line suggests a CAGR of around 1% over the next three years, driven by solid demand for legacy drugs and the approval of new drugs. Shares have outperformed the industry so far this year. However, Revlimid, one of the top revenue generators, is facing generic competition and sales are being adversely impacted.
Shares of Honeywell International have held up a lot better than the peer group as well as the broad market reflecting recovery in commercial flight hours, strong fire products and building management system sales, strong demand in the marine products business and strength in gas processing orders as the key catalysts helping support the stock.
Over the past year, Honeywell shares have lost -2.7% of their value vs. -15.9% decline for the Zacks Diversified Operations industry and the -17.4% decline for the S&P 500 index.
Following a strong third quarter, the company improved its earnings guidance for 2022. Pricing actions and cost-control measures support the company’s margins. Strong free cash flow generation capacity supports the company’s shareholder-friendly activities
Shares of Sony have underperformed the broader market over the past year (-37.5% vs. -17.4% for the S&P 500 index). The company is witnessing weak global macro-economic conditions, inflation, and increasing tension between the United States and China remain major concerns. The company expects its operating income to decline 3.5% year over year, mainly due to a 35% decline in GN&S unit operating income.
Nevertheless, Sony’s performance is gaining from continued strength in Music and Pictures’ segments. The company remains focused on the premium segment of the branded products market to maximize growth. Improving sales at the company Games & Network (GN&S) segment is another tailwind.
The company now expects to sell more than 18-million-unit sales for its PlayStation 5 in the current year. For fiscal 2022, the company now expects overall sales to improve 17% due to higher Music, Pictures and G&NS segment sales. Strategic acquisitions and joint ventures bode well.
Other noteworthy reports we are featuring today include Airbnb, Inc. and Republic Services, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared+40.3%, +48.2%, +67.6%, +94.4%, and+95.3%. Today you can a
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services
For Immediate Release
Chicago, IL – January 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb Co. (BMY - Free Report) , Honeywell International Inc. (HON - Free Report) , Sony Group Corp. (SONY - Free Report) , Airbnb, Inc. (ABNB - Free Report) and Republic Services, Inc. (RSG - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Bristol-Myers, Honeywell and Sony
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb Co., Honeywell International Inc. and Sony Group Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Bristol-Myers Squibb’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+11.3% vs. -13.9%) on the back of solid demand outlook for the company’s blood thinner drug Eliquis and the label expansion of Opdivo. Eliquis is the leading oral anticoagulant drug and continues to experience growth in its market share.
The label expansion of Opdivo into indications for lung cancer, renal cancer and gastric cancer boosted sales. The recent approval of drugs like Opdualag, Breyanzi and Sotyktu will add a new stream of revenues.
According to the Zacks analyst's estimate, the BMY’s top line suggests a CAGR of around 1% over the next three years, driven by solid demand for legacy drugs and the approval of new drugs. Shares have outperformed the industry so far this year. However, Revlimid, one of the top revenue generators, is facing generic competition and sales are being adversely impacted.
(You can read the full research report on Bristol-Myers Squibb here >>>)
Shares of Honeywell International have held up a lot better than the peer group as well as the broad market reflecting recovery in commercial flight hours, strong fire products and building management system sales, strong demand in the marine products business and strength in gas processing orders as the key catalysts helping support the stock.
Over the past year, Honeywell shares have lost -2.7% of their value vs. -15.9% decline for the Zacks Diversified Operations industry and the -17.4% decline for the S&P 500 index.
Following a strong third quarter, the company improved its earnings guidance for 2022. Pricing actions and cost-control measures support the company’s margins. Strong free cash flow generation capacity supports the company’s shareholder-friendly activities
(You can read the full research report on Honeywell International here >>>)
Shares of Sony have underperformed the broader market over the past year (-37.5% vs. -17.4% for the S&P 500 index). The company is witnessing weak global macro-economic conditions, inflation, and increasing tension between the United States and China remain major concerns. The company expects its operating income to decline 3.5% year over year, mainly due to a 35% decline in GN&S unit operating income.
Nevertheless, Sony’s performance is gaining from continued strength in Music and Pictures’ segments. The company remains focused on the premium segment of the branded products market to maximize growth. Improving sales at the company Games & Network (GN&S) segment is another tailwind.
The company now expects to sell more than 18-million-unit sales for its PlayStation 5 in the current year. For fiscal 2022, the company now expects overall sales to improve 17% due to higher Music, Pictures and G&NS segment sales. Strategic acquisitions and joint ventures bode well.
(You can read the full research report on Sony here >>>)
Other noteworthy reports we are featuring today include Airbnb, Inc. and Republic Services, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared+40.3%, +48.2%, +67.6%, +94.4%, and+95.3%. Today you can a
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.